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Three new Ru(II)-peptide bioconjugates were prepared in
pure form andQ3 fully characterized. Unlike in organic
solvents, stable stereoisomers were found by NMR studies
in D2O.
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Ru(II)-Peptide bioconjugates with the cppH linker
(cppH = 2-(2’-pyridyl)pyrimidine-4-carboxylic
acid): synthesis, structural characterization, and
diﬀerent stereochemical features between organic
and aqueous solvents†
FedericaQ2 Battistin,a Daniel Siegmund, b Gabriele Balducci, a Enzo Alessio *a
and Nils Metzler-Nolte *b
Three new Ru(II) bioconjugates with the C-terminal hexapeptide sequence of neurotensin, RRPYIL,
namely trans,cis-RuCl2(CO)2(cppH-RRPYIL-κNp) (7), [Ru([9]aneS3)(cppH-RRPYIL-κNp)(PTA)](Cl)2 (8), and
[Ru([9]aneS3)Cl(cppH-RRPYIL-κNp)]Cl (11), where cppH is the asymmetric linker 2-(2’-pyridyl)pyrimidine-
4-carboxylic acid, were prepared in pure form and structurally characterized in solution. The cppH linker
is capable of forming stereoisomers (i.e. linkage isomers), depending on whether the nitrogen atom ortho
(No) or para (Np) to the carboxylate on C4 in the pyrimidine ring binds the metal ion. Thus, one of the
aims of this work was to obtain pairs of stereoisomeric conjugates and investigate their biological (anti-
cancer, antibacterial) activity. A thorough NMR characterization clearly indicated that in all cases exclu-
sively Np conjugates were obtained in pure form. In addition, the NMR studies showed that, whereas in
DMSO-d6 each conjugate exists as a single species, in D2O two (7) or even three if not four (8 and 11)
very similar stable species form (each one corresponding to an individual compound). Similar results were
observed for the cppH-RRPYIL ligand alone. Overall, the NMR ﬁndings are consistent with the occurrence
of a strong intramolecular stacking interaction between the phenol ring of tyrosine and the pyridyl ring of
cppH. Such stacking interactions between aromatic rings are expected to be stronger in water. This inter-
action leads to two stereoisomeric species in the free cppH-RRPYIL ligand and in the bioconjugate 7, and
is somehow modulated by the less symmetrical Ru coordination environments in 8 and 11, aﬀording
three to four very similar species.
Introduction
The synthesis and biological evaluation of metal bioconju-
gates, in which a targeting molecule binds one or more metal
fragments, is a very active field of bioinorganic chemistry, with
applications in radiolabeling, biosensing, as well as anticancer
and antimicrobial drug development.1 Receptor-binding pep-
tides, such as neurotensin (NT) and octreotide (an analogue of
somatostatin) are among the most actively investigated bio-
molecules. They are characterized by a high aﬃnity for recep-
tors that are overexpressed in several tumors, and thus they
have the potential to internalize selectively the bound metal
into target cancer cells in the so-called “trojan horse
approach”.2,3
In this work we focused on neurotensin (NT), a trideca-
peptide hormone with primary structure pGlu-Leu-Tyr-Glu-
Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu. Three receptors (NTR1–3)
recognize the C-terminal hexapeptide sequence of NT, Arg-Arg-
Pro-Tyr-Ile-Leu or RRPYIL (or NT8–13), which is thus suﬃcient
for recognition and binding (Fig. 1).
Since both NTR1 and NTR3 are upregulated in several
human cancers such as colon, pancreatic, prostate, and lung
cancer,4 metal-bioconjugates with this peptide, or with the
RRPYIL fragment, are interesting candidates for antiprolifera-
†Electronic supplementary information (ESI) available: Crystal and refinement
data, and selected coordination distances and angles for compound 10 (Tables
S1 and S2); minimal inhibitory concentrations (MIC, μg mL−1) for compounds
1–4, 7, 8 and 11 on Gram-positive and Gram-negative bacterial strains (Table S3);
additional 1D and 2D NMR spectra for compounds 7, 8, 10, 11, and
cppH-RRPYIL. CCDC 1863829 (10). For ESI and crystallographic data in CIF or
other electronic format see DOI: 10.1039/c8dt03575jQ1
aDepartment of Chemical and Pharmaceutical Sciences, University of Trieste, Via
Giorgieri 1, 34127 Trieste, Italy. E-mail: alessi@units.it; http://www.dscf.units.it/en
bInorganic Chemistry I – Bioinorganic Chemistry, Ruhr University Bochum, Faculty of
Chemistry and Biochemistry, Bochum, Germany. E-mail: nils.metzler-nolte@rub.de;
http://www.chemie.rub.de/ac1
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tive applications. In the literature there are some examples of
metal-NT8–13 bioconjugates, in which the hexapeptide is
bound – through a peptidic bond – to a supporting ligand of
the metal fragment (e.g. FeCp2 or RuCp2,
5,6 Co2(CO)8,
5 Re(I),7
Pt(IV)8). In one case the peptide is connected to the Rh(III)Cp*
fragment through the Tyr phenol ring.9
In general, the preparation of metal-bioconjugates requires
the use of a bifunctional linker, i.e. a molecule that is capable
of binding firmly the metal ion (typically forming a chelate
ring, for thermodynamic and kinetic stability) and has another
functionality for binding the biomolecule through a covalent
bond. The asymmetric chelating diimine 2-(2′-pyridyl)pyrimi-
dine-4-carboxylic acid (cppH, Fig. 2) was introduced as a new
linker by Spiccia and coworkers in 2009.10 In contrast with the
similar 4′-methyl-2,2′-bipyridine-4-carboxylic acid, cppH has a
straightforward preparation but is capable of forming stereo-
isomers (i.e. linkage isomers): in fact, its pyrimidine ring can
bind to the metal ion either through the nitrogen atom ortho
(No) or para (Np) to the carboxylate on C4. This potential dis-
advantage can, on the other hand, be exploited for preparing
stereoisomeric conjugates. The cppH linker has been used in
the preparation of Ru(II)-bioconjugates with PNA and peptides
for biosensing and biomedical applications; in all the reported
examples it was always bonded through Np.11,12
In recent years we have described the preparation in pure
form and the full characterization of both linkage isomers of
two Ru(II)-cppH complexes, namely trans,cis-RuCl2(CO)2(cppH-
κNp) (1) and trans,cis-RuCl2(CO)2(cppH-κNo) (2) (obtained by
reaction of cppH with the precursor trans,cis,cis-
RuCl2(CO)2(dmso-O)2 (3)), and [Ru([9]aneS3)(cppH-κNp)(PTA)]
(Cl)2 (4) and [Ru([9]aneS3)(cppH-κNo)(PTA)](Cl)2 (5) (obtained
by reaction of cppH with the precursor Ru([9]aneS3)Cl2(PTA)
(6), PTA = 1,3,5-triaza-7-phosphaadamantane) (Fig. 2).13,14
We argued that such pairs of linkage isomers might oﬀer –
in principle – the unique opportunity to prepare unpre-
cedented stereoisomeric Ru-bioconjugates that diﬀer only in
the orientation of the macromolecule with respect to the metal
fragment, and to investigate if they behave diﬀerently in terms
of activity/selectivity in biological experiments.
In this paper we describe the preparation in pure form and
characterization of three novel Ru(II)-peptide bioconjugates,
obtained by linking the cppH carboxylic group to the
C-terminal arginine of the hexapeptide sequence of neuro-
tensin, RRPYIL, through a peptide bond. Since the asymmetric
ligand cppH can generate – besides linkage isomers – also
stereoisomers, highly symmetrical Ru(II) precursors were used
for eliminating this possibility. A detailed NMR investigation
performed in DMSO-d6 and D2O, besides allowing us to estab-
lish the cppH coordination mode, aﬀorded unexpected find-
ings attributed to the establishment in aqueous solution of
strong intramolecular stacking interactions between the linker
and the peptide chain. Cytotoxicity assays against three
diﬀerent cell lines, colon adenocarcinoma (HT-29), breast
cancer (MCF-7) and pancreatic cancer (PT-45), as well as anti-
bacterial tests against both Gram-positive and Gram-negative
strains were performed on both Ru-cppH model complexes
and the bioconjugates.
Results and discussion
Treatment of complex 2 (No isomer) with RRPYIL, adapting a
previously established SPPS peptide coupling procedure,12
aﬀorded bioconjugate 7 (Scheme 1). After preparative HPLC
purification, analytical HPLC showed a single peak, suggesting
that the reaction product was in pure form. In the ESI MS spec-
trum the presence of the molecular peak at 1227.3 m/z
([M + H]+) was consistent with that expected for
RuCl2(CO)2(cppH-RRPYIL), with m/z = 1226.6. At this stage,
however, it was impossible to establish the binding mode of
the cppH linker in 7 (assuming that the geometry of the metal
fragment was unaﬀected by the coupling). In addition, since
the HPLC elution time of the conjugate is mainly dictated by
the peptide fragment, the possibility that compound 7 is actu-
ally a mixture of the two possible linkage isomers could not be
excluded, in case they have undistinguishable retention times.
Fig. 1 Schematic representation of neurotensin; the red box indicates
the C-terminal hexapeptide sequence (fragment 8–13).
Fig. 2 The two pairs of Ru-cppH stereoisomers (linkage isomers) trans,cis-RuCl2(CO)2(cppH-κNp) (1) and trans,cis-RuCl2(CO)2(cppH-κNo) (2),
[Ru([9]aneS3)(cppH-κNp)(PTA)](Cl)2 (4) and [Ru([9]aneS3)(cppH-κNo)(PTA)](Cl)2 (5).
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The Np isomer 1 behaved diﬀerently and none of the mix-
tures of coupling agents tried for diﬀerent reaction times
(from 1 to 7 days), either at room temperature or in a micro-
wave reactor (60 or 80 °C), aﬀorded a product in acceptable
yield.
Given these results, the complementary synthetic strategy
was explored. The hexapeptide RRPYIL was linked to cppH
through a peptidic bond between the carboxylic group of cppH
and the amino group of the terminal arginine using SPPS. The
cppH-RRPYIL moiety was deprotected and cleaved from the
resin, and it was then reacted with the Ru(II) precursor trans,
cis,cis-RuCl2(CO)2(dmso-O)2 (3) in aqueous solution at room
temperature (Scheme 2), i.e. under the conditions that, with
cppH alone, lead to a mixture of the two linkage isomers 1 and
2.13,15 This treatment aﬀorded a bioconjugate whose ESI MS
and analytical HPLC signatures were coincident with those of
7 described above. Thus, within the above mentioned limits,
the two synthetic pathways described in Schemes 1 and 2 led
to the same product 7. Firm proof for the exact coordination
mode of cppH to the ruthenium center was obtained through
a thorough NMR characterization of 7, which is reported
below.
The peptide-functionalized cppH was reacted also with the
precursor Ru([9]aneS3)Cl2(PTA) (6), whose reactivity towards
cppH is known. In 6, the face-capping tridentate ligand [9]
aneS3 gives a geometrical restrain that reduces the number of
possible stereoisomers with asymmetric ligands such as
cppH.14
The treatment of 6 with cppH-RRPYIL, performed in water
at 80 °C (i.e. conditions similar to those that with cppH
aﬀorded a mixture of the linkage isomers 4 and 5),14 yielded
the bioconjugate 8 (Scheme 3). Compound 8 was pure accord-
ing to analytical HPLC, and its molecular peak in the ESI MS
spectrum (1438.6 m/z) was consistent with that expected for
the complex cation [Ru([9]aneS3)(cppH-RRPYIL)(PTA)]
2+
([M − H+]+ at 1438.4 m/z).
A third bioconjugate was obtained from the Ru(II) precursor
Ru([9]aneS3)Cl2(dmso-S) (9). It is known from the literature
that treatment of 9 with a chelating diimine ligands such as
2,2′-bipyridine (bpy) in refluxing ethanol leads selectively to
[Ru([9]aneS3)Cl(bpy)]Cl.
16,17 Similarly, we found that [Ru([9]
aneS3)Cl(cppH)]Cl (10) precipitates spontaneously when 9 is
reacted with cppH in refluxing water (Scheme 4). Compound
10 was fully characterized by NMR spectroscopy, mass spec-
trometry, and its single-crystal X-ray structure was also deter-
mined (Fig. 3).
The single crystal X-ray analysis established that cppH is
bound via Np, i.e. 10 is [Ru([9]aneS3)Cl(cppH-κNp)]Cl. The 1H
NMR spectrum in D2O shows two sets of six resonances for
cppH, due to the equilibrium with the aqua species
[Ru([9]aneS3)(cppH-κNp)(OH2)]+ (10aq) upon chloride hydro-
Scheme 1 The ﬁnal step of the synthesis of 7 using SPPS.
Scheme 2 The alternative synthesis of 7.
Scheme 3 Synthesis of bioconjugate 8.
Scheme 4 Synthesis of the model complex [Ru([9]aneS3)Cl(cppH-κNp)]
Cl (10).
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lysis. The aromatic resonances of 10aq are slightly downfield
shifted (ca. 0.1 ppm) compared to those of the parent complex
10, and their relative intensity decreases upon adding an
excess of NaCl (ESI). The cppH chemical shifts are consistent
with the Np coordination found in the solid state (see below).
The formation of the No isomer of 10 was not observed: the
same linkage isomer was obtained also when the reaction
between 9 and cppH was performed at room temperature.
The reaction between 9 and cppH-RRPYIL, performed in
water at 80 °C, aﬀorded the bioconjugate 11 (Scheme 5).
After HPLC purification, the ESI MS molecular peak
found for 11 (13 158 m/z) was in agreement with that expected
for the cationic species [Ru([9]aneS3)Cl(cppH-RRPYIL)]
+
(1315.1 m/z).
Also for bioconjugates 8 and 11, as for 7 above, it was not
possible, at this stage, to assess the binding mode of cppH or
even whether each product was actually pure or a mixture of
the two possible linkage isomers (always assuming that their
biophysical properties were dominated by the peptide, and
they thus might have undistinguishable retention times at
HPLC analysis).
With the aim of determining the coordination mode of the
cppH-RRPYIL unit, the bioconjugates 7, 8 and 11 were sub-
jected to a detailed analysis by NMR spectroscopy (including
2D COSY and HSQC spectra). Spectra were recorded in DMSO-
d6 and D2O, where all compounds are completely soluble at
NMR concentrations.
NMR characterization of the bioconjugates in DMSO-d6
The 1H NMR spectrum in DMSO-d6 of 7, obtained by either
one of the two synthetic approaches, confirmed the excellent
purity of the conjugate. A comparison of the spectrum, that
presents six well-resolved signals for coordinated cppH in the
aromatic region, with those of the two linkage isomers trans,
cis-RuCl2(CO)2(cppH-κNp) (1) and trans,cis-RuCl2(CO)2
(cppH-κNo) (2) strongly suggests that in this bioconjugate the
cppH-RRPYIL is bonded through the Np (Fig. 4, see also
Table 1). In fact, all the cppH resonances of 7, and in particu-
lar those of the protons 5 and 6 on the pyrimidine ring that
are most aﬀected by diﬀerences in the binding mode,13,14 have
chemical shifts very similar to those of 1. The only exception is
the signal of H3′ on the pyridine ring (see below). Accordingly,
7 was formulated as trans,cis-RuCl2(CO)2(cppH-RRPYIL-κNp).
This finding was rather surprising, considering that in the
starting complex 2 cppH was bound through No, and implies
that, during the SPPS synthesis, isomerization to the Np
species occurred. In addition, the Np precursor 1 aﬀorded no
bioconjugate when reacted with RRPYIL.
The aromatic region of the spectrum of 7 shows also several
resonances that have no correlation crosspeaks with carbon reso-
nances in the 1H–13C HSQC spectrum (ESI) and, based on the
1H–1H COSY spectrum, were attributed to NH (or OH) protons of
the peptide (see below). The two sharp doublets at ca. 7.0 and
6.6 ppm, correlated in the 1H–1H COSY spectrum, belong to the
ortho and meta protons of the tyrosine phenol ring.
The 1H NMR spectra in DMSO-d6 of [Ru([9]aneS3)
(cppH-RRPYIL)(PTA)]2+ (8) and [Ru([9]aneS3)Cl(cppH-RRPYIL)]
+
(11) have features similar to that of 7. In the aromatic region
both show a single set of six signals for the metal-bound
cppH-RRPYIL and other signals for the amidic protons, par-
tially overlapping with the cppH resonances, that in the 1H–1H
COSY spectrum have crosspeaks with protons in the peptide
zone (ESI). The comparison of the cppH resonances of 8 and
11 with those of the model complexes with unmodified cppH
4, 5, and 10 suggests that in both bioconjugates the
cppH-RRPYIL unit is again bound through Np (see also
Table 1). As found for 7, the resonance of the pyridine ring
proton 3′ is downfield shifted compared to the model com-
plexes and falls at higher frequency than 6′ (ESI). The two reso-
nances are easily distinguished in the 1H–13C HSQC spectrum
since 3′ has a correlation peak with a carbon atom at ca.
127 ppm, while 6′ with a carbon at 155 ppm (see ESI†).
Typically, in Ru(II)-cppH complexes the resonances of protons
6 and 6′, that are adjacent to the bonded nitrogen atoms, are
the most downfield-shifted signals.13,14 In this case, some
Fig. 3 X-ray molecular structure (50% probability ellipsoids) of [Ru([9]
aneS3)Cl(cppH-κNp)]Cl·0.45H2O (10). The chloride counterion and the
crystallization water molecule are omitted for clarity. Coordination dis-
tances (Å): Ru1–Cl1 = 2.4316(7), Ru1–N31 = 2.094(3), Ru1–N32 = 2.096
(2), Ru1–S21 = 2.305(1), Ru1–S22 = 2.2943(8), Ru1–S23 = 2.2787(8).
Scheme 5 Synthesis of bioconjugate 11.
Paper Dalton Transactions
4 | Dalton Trans., 2018, 00, 1–15 This journal is © The Royal Society of Chemistry 2018
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
interaction between the peptide and the pyridine ring might
be invoked to explain the change of chemical shift for the
signal of proton 3′. Finally, the 31P{1H} NMR spectrum of 8
shows a broad singlet centered at −39.1 ppm, i.e. at a
frequency consistent with PTA trans to S and similar to that of
the corresponding model complexes 4 and 5 with unmodified
cppH (−34.9 for the Np isomer and −35.0 for the No isomer,
recorded in D2O instead of DMSO-d6).
14
In conclusion, according to the above results, the bioconju-
gate 8 was formulated as [Ru([9]aneS3)(cppH-RRPYIL-κNp)
(PTA)]2+ and 11 as [Ru([9]aneS3)Cl(cppH-RRPYIL-κNp)]+.
NMR characterization of the bioconjugates in D2O
Quite unexpectedly, we found that the 1H NMR spectrum of
the bioconjugate 7 presents twice the number of cppH-RRPYIL
resonances in the aromatic region (Fig. 5) when the compound
was dissolved in D2O rather than in DMSO-d6. The two sets of
four resonances for the protons on the pyridine ring of
cppH-NT are well resolved (the assignments of 3′ and 6′ are
consistent with the 13C NMR chemical shifts, obtained
through the 1H–13C HSQC spectrum), whereas the signals for
protons 5 and 6 of the pyrimidine ring are partially or comple-
tely overlapping. Each of these integrates as the sum of the two
resonances of each proton of the pyridine ring. Thus, the
proton spectrum of 7 suggests that in aqueous solution there
are two species in ca. 3 : 2 ratio (according to the integration of
the 3′ and 6′ pairs of resonances) that most likely have the pyri-
midine rings in very similar environments (overlapping reso-
nances) and the pyridine rings in relatively diﬀerent environ-
ments. It is worth noting that typically the opposite occurs in
case of linkage isomers of cppH, i.e. the resonances of the pyri-
midine protons are aﬀected much more than those of the pyri-
dine protons by the diﬀerent binding mode.13,14 Since in trans-
{RuCl2} fragments chloride hydrolysis occurs very slowly and
to a small extent (and was not observed in the corresponding
cppH complexes 1 and 2), we exclude that the two species
derive from this process.
The region of the peptide resonances is obviously more
complicated. However, it is possible to distinguish clearly two
sets of resonances (two doublets each) for the aromatic
protons of Tyr that are basically in the same 3 : 2 intensity ratio
as the cppH protons (see ESI†). They are pairwise connected in
Fig. 4 Aromatic region of the 1H NMR spectra (DMSO-d6) of trans,cis-RuCl2(CO)2(cppH-κNo) (2) (top), trans,cis-RuCl2(CO)2(cppH-κNp) (1) (middle)
and trans,cis-RuCl2(CO)2(cppH-RRPYIL) (7) (bottom). Only the resonances of cppH protons are labeled; see insert for labeling scheme.
Table 1 1H NMR chemical shifts (D2O) for the resonances of H5 and H6
(pyrimidine ring protons) for model complexes with cppH (both Np and
No linkage isomers, when available) and the corresponding bioconju-
gates with cppH-RRPYIL. Δδ = δbioconjugate − δcomplex
Compound H6 H5
trans,cis-RuCl2(CO)2(cppH-κNp) (1) 9.64 8.22
trans,cis-RuCl2(CO)2(cppH-RRPYIL) (7) 9.79 8.38
Δδ 0.15 0.15
trans,cis-RuCl2(CO)2(cppH-κNo) (2) 9.17 7.72
trans,cis-RuCl2(CO)2(cppH-RRPYIL) (7) 9.79 8.38
Δδ 0.62 0.66
[Ru([9]aneS3)(cppH-κNp)(PTA)]2+ (4) 9.28 8.16
[Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (8) 9.42 8.26
Δδ 0.14 0.10
[Ru([9]aneS3)(cppH-κNo)(PTA)]2+ (5) 9.13 7.64
[Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (8) 9.42 8.26
Δδ 0.29 0.62
[Ru([9]aneS3)Cl(cppH-κNp)]+ (10) 9.52 8.11
[Ru([9]aneS3)Cl(cppH-RRPYIL)]
+ (11) 9.55 8.16
Δδ 0.03 0.05
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the 1H–1H COSY spectrum according to their relative intensity.
We observe that in D2O also the signals of the peptide chain in
the upfield region are split in two sets, even though not always
resolved. The splitting is clearly evident for the CHα and for the
leucine and isoleucine methyl resonances (CHδ and CHγ), where
diﬀerences in chemical shift up to 0.2 ppm are observed between
pairs of related signals (ESI). These pairs of related multiplets are
also readily spotted in the HSQC spectrum, where they are pair-
wise coupled to the corresponding carbon signal; in fact, since
the 13C spectrum seems less aﬀected than the 1H spectrum, the
resonances of the corresponding carbon atoms in the two sets of
signals have basically identical chemical shifts.
In order to shed further light on the nature of the two
isomers that are observed in aqueous solution, a number of
additional NMR experiments were performed. First, an
increase in the temperature (up to 65 °C) induced no signifi-
cant change in the aromatic region of the 1H NMR spectrum,
thus suggesting that the two species are not in a conformation-
al equilibrium. Then, the eﬀect of pH on the NMR spectrum
was investigated. The pD of the original D2O solution (ca. 3.5)
was gradually increased to 8.0 by stepwise addition of small
amounts of a NaOD solution, and spectra were recorded after
each step. Also in this case no significant change was observed
in the aromatic region of the spectrum. Similarly unchanged
was the spectrum of the final pD 8.0 solution when it was
recorded again at higher temperatures (up to 65 °C).
The 1H NMR spectrum of 8 in D2O is even more complex
than that of 7. In the aromatic region it is possible to dis-
tinguish at least three diﬀerent sets of resonances, in ca.
1 : 1.5 : 2.5 ratio (red/green/blue in Fig. 6), that diﬀer mainly in
the shifts of the pyridine ring protons. Two sets (red and green
in Fig. 6) are almost completely overlapping, with only the
resonances of proton 4′ being resolved. Moreover, each signal
of the “blue” set seems to be the sum of two very similar,
almost completely overlapping resonances (e.g. inspect the
signal of H6′ in Fig. 6). In conclusion, compound 8 in aqueous
solution is most likely a mixture of four very similar species.
Integration of the cppH resonances compared with those of
PTA and of the aromatic protons of Tyr, established that in
each species PTA is still bound to the ruthenium center and
the peptide chain is connected to cppH, i.e. each species is
integer and has the same coordination environment. Also in
this case an increase in temperature (up to 65 °C) and an
increase in pD (from ca. 3.0 to ca. 8.0) left the 1H NMR spec-
trum virtually unchanged.
The 1H NMR spectrum of 11 in D2O is further complicated,
compared to that of 8, by the partial hydrolysis of the chloride.
In fact, the addition of excess of NaCl (ca. 0.5 M) simplifies the
spectrum since it reverts the aquation equilibrium, leaving
only the resonances of non-hydrolyzed species (Fig. 7). This
finding is similar to that observed for the model complex 10
with unmodified cppH (ESI).
From the 1H–1H COSY spectrum of the cppH-NT region in
11 it is possible to distinguish at least three diﬀerent sets of
signals for three diﬀerent major species in ca. 1 : 1 : 3 ratio
(red/green/blue in Fig. 8). The three species have very similar
(overlapping) resonances for the pyrimidine protons 5 and 6
(again suggesting that they are not linkage isomers), whereas
several resonances of the pyridine protons are well resolved. In
more detail, the two minor species (red and green) have very
similar resonances for the pyridine protons, which are rather
diﬀerent from those of the main species (blue). In particular,
the resonances of the pyridyl protons 3′ and 4′ of the minor
species are shifted upfield compared to those of the main
species. Integration of the 1H NMR signals established that in
each species the peptide chain is still attached to cppH.
Fig. 5 Aromatic region of the 1H–1H COSY spectrum of 7 in D2O, with labeled cppH resonances (blue for the major isomer, red for the minor one).
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Finally, in the 1H NMR spectra of 8 and 11 in D2O the com-
plexity of the cppH region is mirrored by that of the aromatic
protons of Tyr (see ESI†). The number of Tyr doublets in the
spectra of 8 and 11 is consistent with the presence of three or
more species, as indicated by the cppH region.
NMR characterization of cppH-RRPYIL in DMSO-d6 and D2O
Intrigued by the results reported above, we performed an NMR
characterization of the cppH-RRPYIL ligand alone. Consistent
with the above described findings, cppH-RRPYIL shows a
single set of signals in DMSO-d6 (Fig. 9). A similar single set of
resonances was found also in CD3OD. However, in D2O all
resonances – including those of the peptide chain in the
upfield region of the spectrum – are split in two sets in ca.
1 : 1.7 ratio (Fig. 9), an unambiguous indication that this
phenomenon does not depend primarily on the coordination
of cppH to ruthenium, even though it seems to be modulated
by the coordination environment (diﬀerent ratio of the
isomers for 7, and additional isomers for 8 and 11). The spec-
tral patterns of cppH-RRPYIL in each of the two solvents are
similar to those observed for 7 (in the corresponding solvent),
i.e. the conjugate that aﬀords the simplest spectra, thus allow-
ing fruitful comparisons to be made.
The 1D and 2D NMR characterization of cppH-RRPYIL in
DMSO-d6 (ESI), compared with the available literature data,
18
allowed us to locate all the NH signals in the downfield region.
Fig. 6 Downﬁeld region of the 1H–1H COSY spectrum in D2O of [Ru([9]aneS3)(cppH-RRPYIL)(PTA)]
2+ (8) with labeled cppH resonances (a diﬀerent
color for each isomer).
Fig. 7 Downﬁeld region of the 1H NMR spectrum of [Ru([9]aneS3)Cl(cppH-RRPYIL)]
+ (11) after dissolution in D2O (top) and after addition of an
excess of NaCl (bottom).
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They have no correlation crosspeaks with carbon resonances
in the 1H–13C HSQC spectrum (see ESI†). Five of them corre-
late in the 1H–1H COSY spectrum they with the respective Cα
protons, whose resonances fall between 4.0 and 4.6 ppm (ESI),
and were thus assigned to the amidic protons of the peptide.
By comparison with the NMR spectrum of 7 (Fig. 10) we notice
that upon coordination to the {trans,cis-RuCl2(CO)2} fragment,
only the NH resonance at ca. 8.8 ppm (blue dot) is downfield
shifted (as well as those of cppH, as expected), and it was thus
assigned to the amidic proton of the arginine directly bound
to cppH. Remarkably, addition of small amounts of D2O to the
DMSO-d6 solution of cppH-RRPYIL (Fig. 11) induced a large
shift of this resonance (blue dot) to higher frequencies (ca.
0.8 ppm after addition of 10% D2O). Taken together, these
observations suggest that this proton is involved in an
H-bonding interaction with cppH (arguably with the pyridine
N atom), that is perturbed by the addition of water. Based on
the 1H–1H COSY and 1H–13C HSQC spectra, and consistent
Fig. 8 Downﬁeld region of the 1H–1H COSY spectrum in D2O + NaCl of [Ru([9]aneS3)Cl(cppH-RRPYIL)]
+ (11) with labeled cppH resonances (a
diﬀerent color for each isomer).
Fig. 9 1H NMR spectra (aromatic region) of cppH-RRPYIL in DMSO-d6 (top) and D2O (bottom). In the latter, the resonances of the major isomer are
labeled in black, and those of the minor one in blue.
Paper Dalton Transactions
8 | Dalton Trans., 2018, 00, 1–15 This journal is © The Royal Society of Chemistry 2018
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
with literature data,18 the two multiplets at ca. 7.4–7.5 were
assigned to the NHε of the two arginines. The rather broad
resonance at ca. 9.17 ppm, that has no correlation peaks in the
1H–1H COSY and 1H–13C HSQC spectra, was assigned to the
proton of the hydroxyl group of the Tyrosine. Furthermore, we
found that the two broad singlets at ca. 7.2 and 7.0 ppm
(green dots) disappear upon addition of very small amounts of
D2O (2%, Fig. 11), and were thus assigned to the terminal
CONH2 protons, whose H/D exchange rate is expected to be
much faster than that for amidic protons. Further addition of
D2O (up to 50%) led to the progressive disappearance of the
NH (and OH) resonances and, more interestingly, to the
appearance of a second set of resonances (Fig. 11). Even
though in the 1 : 1 DMSO-d6/D2O mixture the resonances are
hardly comparable to those found in pure D2O, both in terms
of relative intensities and chemical shifts, the trend suggests
that the growing “blue” set closely resembles that found in
D2O.
A number of experiments were performed on the pure D2O
solution of cppH-RRPYIL. An increase in temperature up to
65 °C led to a general broadening of all resonances and loss of
resolution (ESI), but no clear coalescence between pairs of
corresponding resonances in the two sets was observed,
suggesting that they do not belong to species in conformation-
al equilibrium. Consistent with this finding, we observed no
exchange cross-peaks between the corresponding resonances
Fig. 10 1H NMR spectra (aromatic region) of cppH-RRPYIL (top) and trans,cis-RuCl2(CO)2(cppH-RRPYIL) (7) (bottom) in DMSO-d6.
Fig. 11 1H NMR spectra (aromatic region) of cppH-RRPYIL in DMSO-d6 (top), with 10% ca. of D2O (middle) and with 50% of D2O (bottom). The new
set of resonances has blue labels.
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in a ROESY spectrum. A three-fold increase in the concen-
tration of cppH-RRPYIL induced no significant change in the
1H NMR spectrum. Finally, a pD titration from ca. 3.5 to ca.
10.0 led to no significant change in the ratio of the two sets of
signals, besides the expected shifts of the cppH resonances
due to the deprotonation of the pyridyl nitrogen atom.14
Furthermore, all changes in chemical shifts were fully reversed
upon lowering the pD again.
Overall, the NMR findings with cppH-RRPYIL, that are
similar to those observed for the conjugate 7, are consistent
with two hypotheses: (1) either in DMSO-d6 (and CD3OD) there
is a strong interaction between the pyridine ring of cppH and
the peptide chain, leading to a single species, that is partially
disrupted by the addition of water, or the opposite is true, i.e.
(2) an interaction, that is absent in DMSO-d6 (and CD3OD),
occurs in water. In addition, we believe that such an inter-
action is intra-rather than inter-molecular (since it does not
depend on concentration), and it is not related to hydrogen
bonding, since that would be expected to be strongly aﬀected
by changes in pH.
In the transition from pure DMSO-d6 to DMSO-d6/D2O mix-
tures, the downfield region of the spectrum clearly shows that
most of the resonances in the growing set are shifted to lower
frequencies (resembling what found in pure D2O). Tyrosine is
the amino acid on the peptide sequence whose signals are
most aﬀected from the transition from DMSO-d6 to D2O, with
an upfield shift up to ca. 0.4 ppm for both doublets. In the
cppH region, the most aﬀected resonances are those of
protons 6′ and 3′ on the pyridine ring, with upfield shifts of ca.
0.15 ppm from the major (“black”) to the minor (“blue”) set.
These upfield shifts are consistent with the occurrence of a
stacking interaction between the phenol ring of tyrosine and
the pyridyl ring of cppH. An “educated model” of this intra-
molecular interaction is presented in Fig. 12.19 Regretfully, a
series of 1D NOE experiments, in which each one of the four
Tyr doublets was in turn saturated, aﬀorded no NOE enhance-
ment with the resonances of the pyridine ring protons (as one
might expect in case of a stacking interaction).
Numerous attempts to grow single crystals of each conju-
gate as well as of cppH-RRPYIL by the hanging-drop method,
were regretfully also unsuccessful.
Antiproliferative and antimicrobial activity
The antiproliferative properties of conjugates 7, 8, and 11 (as
well as of the Ru-cppH model compounds 1–4 for comparison)
were assessed against three diﬀerent cell lines:20 colon adeno-
carcinoma (HT-29), breast cancer (MCF-7) and pancreatic
cancer (PT-45). All the cell lines were treated for 48 hours with
increasing concentrations of each compound. None of the
investigated compounds showed antiproliferative activity, even
at the highest investigated concentration of 200 µM. Given the
absence of activity, the targeting properties of the conjugates
were not investigated.
The antimicrobial activity was assessed on a representative
selection of Gram-positive (B. subtilis and two strains of
S. aureus) and Gram-negative (E. coli, A. baumannii and
P. aeruginosa) bacterial strains. The lowest concentration inhi-
biting visible growth was reported as minimal inhibitory con-
centration (MIC, see ESI†). Compounds 1–4 were found to be
inactive against both Gram-positive and Gram-negative strains.
Among the bioconjugates, 11 resulted to be the most active,
with a moderate activity against E. coli (MIC = 32 μg mL−1) and
a low activity against B. subtilis (MIC = 256 μg mL−1).21
Conclusions
The diimine cppH linker was exploited for preparing three
new Ru(II) bioconjugates with the C-terminal hexapeptide
sequence of neurotensin, RRPYIL, namely trans,
cis-RuCl2(CO)2(cppH-RRPYIL-κNp) (7), [Ru([9]aneS3)
(cppH-RRPYIL-κNp)(PTA)](Cl)2 (8), and [Ru([9]aneS3)Cl
(cppH-RRPYIL-κNp)]Cl (11). Two complementary synthetic
approaches were investigated: (i) attachment of RRPYIL to the
carboxylic group of cppH on pure Ru-cppH linkage isomers
(7), and (ii) preparation of cppH-RRPYIL followed by its coordi-
nation to suitable Ru(II) precursors with two adjacent labile
ligands (7, 8, 11).
Since cppH is capable of forming stereoisomers, depending
on whether the nitrogen atom ortho (No) or para (Np) to the car-
boxylate on C4 in the pyrimidine ring is used for metal
binding, one of the aims of this work was that of obtaining
pairs of stereoisomeric conjugates (i.e. linkage isomers) and
evaluating their biological activity. A thorough NMR character-
ization clearly indicated that in all cases, regardless of the syn-
thetic procedure adopted and of the stereochemistry of the
precursor, exclusively Np linkage-isomers were obtained in
pure form, even when No isomers were used as starting
material. However, the NMR studies provided also unexpected
Fig. 12 Model (H atoms omitted) of the possible intramolecular stack-
ing interaction occurring in aqueous solution between the phenol ring
of tyrosine and the pyridyl ring of cppH in cppH-RRPYIL. For the sake of
clarity this cartoon, even though realistic,19 is just a suggestion, and not
supported by e.g. NOE or ROESY NMR data.
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findings: whereas in DMSO-d6 the NMR spectra are rather
straightforward and present a single set of resonances, the
spectra of the same samples in D2O show that, in this solvent,
each bioconjugate exists as two (7) or even three if not four
(8 and 11) very similar species (each one corresponding to the
integer compound). The spectra were not aﬀected by an increase
in temperature and by changing the pH of the solution. Since
the NMR spectra of the diﬀerent species diﬀer mainly in the
resonances of the pyridine ring of cppH-RRPYIL, we argue that
they do not diﬀer in the Ru coordination environment (includ-
ing cppH linkage isomers) but derive likely from some strong
intra- or intermolecular interaction between the peptide and the
pyridine ring of cppH (see below).
This conclusion was confirmed by the NMR investigation
performed on the cppH-RRPYIL ligand alone: it exists as a
single species in DMSO-d6 (and CD3OD), but as two species in
ca. 1 : 1.7 ratio in D2O. Overall, the NMR findings with
cppH-RRPYIL, that are similar to those observed for 7, are con-
sistent with the occurrence of a strong intramolecular stacking
interaction between the phenol ring of tyrosine and the pyridyl
ring of cppH (Fig. 12). Stacking interactions between aromatic
rings are expected to be stronger in water (solvophobic eﬀect).
This interaction, that leads to two stereoisomeric species in
the free cppH-RRPYIL ligand and in the bioconjugate 7, is
somehow modulated by the less symmetrical Ru coordination
environments in 8 and 11, aﬀording three-four very similar
species.
Firm proof for our interpretation could be obtained from a
single crystal X-ray structure. However, even though we tried
hard, no suitable crystals could be obtained. So, from the
NMR data alone, we can deduce the above conclusions, but
these – even though fully consistent with all experimental data
– certainly have a greater degree of uncertainty than an X-ray
structure would have, and we are unable to establish the
stereochemical diﬀerences between the stereoisomers found
in D2O. Nevertheless, we stress that detailed NMR investi-
gations of metal bioconjugates are virtually absent in the lit-
erature, thus impeding comparisons: the nature and purity of
the conjugates are typically assessed only by mass spec-
troscopy and HPLC, respectively. We also remark that the
phenomenon of stereoisomer formation occurs exclusively in
D2O, and that it would have escaped detection by an NMR
investigation performed in DMSO-d6 only. Therefore, our find-
ings strongly suggest that in the future the characterization of
new metal conjugates – as well as the reinvestigation of known
ones – should include detailed NMR investigations in multiple
solvents, including D2O. It would be of particular interest to
establish if the formation of stereoisomers in aqueous solu-
tions is a characteristic feature of cppH-RRPYIL or if it occurs
also with other linker-peptide combinations.
Finally, neither the bioconjugates 7, 8, and 11 nor the Ru-
cppH model compounds 1–4 showed any significant antiproli-
ferative or antibacterial activity. For comparison, NT8–13 metal
bioconjugates with the Co2(CO)8 fragment or a Pt(IV) complex
were previously shown to be moderately toxic towards some
cancer cell lines.5,8
Experimental section
Materials
All chemicals were purchased from Sigma-Aldrich and used as
received. Solvents were of reagent grade. The precursors trans,
cis,cis-RuCl2(CO)2(dmso-O)2 (3),
22 Ru([9]aneS3)Cl2(PTA) (6),
23
and Ru([9]aneS3)Cl2(dmso-S) (9),
24 and the linker
cppH·HNO3,
10 were synthesized as described in the literature.
Instrumental methods
Mono- and bi-dimensional (1H–1H COSY, 1H–13C HSQC) NMR
spectra were recorded at room temperature on a Varian 400 or
500 spectrometer (1H: 400 or 500 MHz, 31P{1H}: 161 or
202 MHz). 1H chemical shifts were referenced to the peak of
residual non-deuterated solvent (δ = 2.50 for DMSO-d6 and
3.31 for CD3OD) or were measured relative to the internal stan-
dard DSS (δ = 0.00) for D2O. Carbon resonances were assigned
through the HSQC spectra. 31P{1H} chemical shifts were refer-
enced to external 85% H3PO4 at 0.00 ppm. ESI mass spectra
were collected in the positive mode on a Bruker Esquire 6000
spectrometer. Elemental analysis for 10 was performed on a
Thermo Flash 2000 CHNS/O analyzer in the Department of
Chemistry of the University of Bologna (Italy).
Analytical HPLC was performed on a Smartline instrument
(Knauer) with a Reprosil-Pur C-18 reversed-phase column at a
flow rate of 1.0 mL min−1. Preparative HPLC was performed on
a Varian Prostar with a HIBAR Lichrospher 100 RP-18e
reversed-phase column at a flow rate of 20 mL min−1.
Analytical and preparative runs were performed with a linear
gradient of 5% buﬀer B per min starting at 5 min of buﬀer A
(buﬀer A = H2O/MeCN/TFA 95 : 5 : 0.1, v/v/v, buﬀer B = MeCN/
H2O/TFA 95 : 5 : 0.1, v/v/v) was used.
Lyophilization was performed on an ALPHA 1–4 LDplus lyo-
philizator (Martin Christ, Osterode am Harz, Germany).
Attempts to grow crystals of each conjugate as well as of
cppH-RRPYIL by the hanging-drop method were done at
diﬀerent pH values (pH = 5 and 5.5 (sodium citrate), pH = 6
and 6.5 (MES = 2-(N-morpholino)ethanesulfonic acid), pH = 8
(TRIS = tris(hydroxymethyl)aminomethane)), in the presence
of diﬀerent salts (NaCl (from 0.1 to 0.3 M), MgCl2 (from 0.1 to
0.5 M), and (NH4)2SO4 (from 10% to 60% of a saturated solu-
tion)), and using two types of PEG (PEG300, and PEG4000) as
dehydrating agent.
Cell cultures and cytotoxicity
Dulbecco’s Modified Eagle’s Medium (DMEM), containing
10% fetal calf serum, and 1% penicillin and streptomycin, was
used as growth medium. MCF-7, HT-29 and PT-45 cells were
detached from the wells with trypsin and EDTA, harvested by
centrifugation and re-suspended again in cell culture medium.
The assays have been carried out on 96 well plates with 6000
cells per well for each cell line. After 24 h of incubation at
37 °C and 10% CO2, the cells were treated with the compounds
1–4, 7, 8, and 11 at 1, 10, 20, 40, 80, 100, 200 µM concentration
(with DMSO concentrations of 0.5%) with a final volume of
200 µL per well. For a negative control, one series of cells was
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left untreated. The cells were incubated for 48 h followed by
adding 50 µL MTT (2.5 mg mL−1). After an incubation time of
2 h, the medium was removed and 200 µL DMSO were added.
The formazan crystals were dissolved and the absorption was
measured at 550 nm, using a reference wavelength of 620 nm.
Antimicrobial activity
The antimicrobial activity of compounds 1–4, 7, 8, 11 was eval-
uated by determining of the minimal inhibitory concentration
(MIC, μg mL−1) according to a previously described method.25
Bacillus subtilis DSM 402, Staphylococcus aureus DSM 20231,
and Staphylococcus aureus ATCC 43300 were chosen as Gram-
positive test strains. Escherichia coli DSM 30083, Acinetobacter
baumannii DSM 30007, and Pseudomonas aeruginosa DSM
50071 served as Gram-negative strains in these experiments.
With the exception of P. aeruginosa (Mueller-Hinton II broth),
all strains were cultured in Mueller-Hinton broth. The com-
pounds were dissolved in DMSO to obtain stock solutions of
10 mg mL−1. Serial dilution was carried out with a Tecan
Freedom Evo 75 liquid handling workstation (final concen-
trations range: 0.5 to 512 μg mL−1). The obtained serial
dilutions were inoculated with 5 × 105 bacteria per mL taken
from late exponential cultures grown in the above mentioned
media (total volume 200 μL per well). Cells were incubated for
16–18 h at 37 °C. The lowest concentration inhibiting visible
bacterial growth is given as MIC.
X-ray diﬀraction
Data collections were performed at the X-ray diﬀraction beam-
line (XRD1) of the Elettra Synchrotron of Trieste (Italy)
equipped with a Pilatus 2 M image plate detector.
Collection temperature was 100 K (nitrogen stream supplied
through an Oxford Cryostream 700); the wavelength of the
monochromatic X-ray beam was 0.700 Å and the diﬀracto-
grams were obtained with the rotating crystal method. The
crystals were dipped in N-paratone and mounted on the gonio-
meter head with a nylon loop. The diﬀraction data were
indexed, integrated and scaled using the XDS code.26 The
structures were solved by the dual space algorithm
implemented in the SHELXT code.27 Fourier analysis and
refinement were performed by the full-matrix least-squares
methods based on F2 implemented in SHELXL.28 The Coot
and SHELXLE programs were used for modeling.29,30
Anisotropic thermal motion was allowed for all non-hydrogen
atoms. Hydrogen atoms were placed at calculated positions
with isotropic factors U = 1.2 × Ueq, Ueq being the equivalent
isotropic thermal factor of the bonded non hydrogen atom.
Crystal data and details of refinements are in the ESI.†
Solid-phase synthesis of the hexapeptide RRPYIL
The hexapeptide RRPYIL was synthesized manually at room
temperature by using a Fmoc-protecting strategy and a Rink
amide resin. Reactions were carried out in polypropylene
syringes on a mechanical shaker. The resin was swollen in
DMF before use.
Fmoc-deprotection: 20% piperidine in DMF (5 mL) was
added to the resin for 2 × 10 min. After each coupling and de-
protection step, the resin was thoroughly washed with DMF,
DCM and DMF (5 mL each).
Coupling: Fmoc-protected amino acids (4 equiv.: 648.7 mg
for Arg, 337.4 mg for Pro, 459.5 mg for Tyr, 353.4 mg for Ile
and Leu) were pre-activated with TBTU (234.1 mg, 4 equiv.),
HOBT (135.1 mg, 4 equiv.) and DIPEA (349 μL, 8 equiv.) in
DMF (1–2 mL) for 1 min, mixed with the resin and shaken for
1 h.
Final cleavage from the resin and side chain deprotection
of the peptide was accomplished by using a mixture of 90%
TFA, 5% TIS and 5% H2O (3 mL) for 4 h at room temperature.
The cleaved peptide was precipitated with ice-cold diethyl
ether (30 mL), centrifuged and washed two times with diethyl
ether (30 mL), and then lyophilized and purified by preparative
HPLC. [C38H65N13O7]: (MW: 815.51). Analytical HPLC: tR =
14.8 min, ESI mass spectrum: 816.6 m/z, [M + H]+ (calcd
816.10).
Synthesis of cppH-RRPYIL
The coupling of the hexapeptide RRPYIL with cppH·HNO3 was
performed as with the aminoacids: cppH (211.3 mg, 4 equiv.)
was pre-activated with TBTU (187.2 mg, 4 equiv.), HOBT
(108.1 mg, 4 equiv.) and DIPEA (175 μL, 5 equiv.) in DMF
(1–2 mL) for 1 min, mixed with the resin and shaken for 2 h.
Final cleavage from the resin and side chain deprotection of
the peptide was accomplished by using a mixture of 90% TFA,
5% TIS and 5% H2O (2.8 mL) for 4 h at room temperature. The
cleaved cppH-RRPYIL was precipitated with ice-cold diethyl
ether (30 mL), centrifuged and washed two times with diethyl
ether (30 mL), and then lyophilized and purified by preparative
HPLC. Yield of purified product: 120.8 mg (0.120 mmol, 62%).
[C48H70N16O8]: (MW: 998.54). Selected
1H NMR resonances
(DMSO-d6), δ (ppm): 9.25 (d, 1H, H6), 9.17 (br s, 1H, OH Tyr),
8.88 (d, 1H, NH), 8.82 (d, 1H, 6′), 8.52 (m, 2H, 3′ + NH), 8.06
(m, 2H, 4′ + 5), 7.89 (m, 2H, NH + NH), 7.81 (d, 1H, NH), 7.63
(t, 1H, 5′), 7.50 (m, 1H, NHε Arg), 7.44 (m, 1H NHε Arg), 7.01,
6.62 (d, 4H, H2,6 and H5,3 Tyr), 4.7–4.1 (m, 6H, Hα peptide).
Selected 13C NMR resonances from the HSQC spectrum
(DMSO-d6), δ (ppm): 161.0 (C6), 150.2 (C6′), 138.0 (C4′), 130.5
(C Tyr), 126.1 (C5′), 124.4 (C3′), 118.0 (C5), 115.6 (C Tyr),
59.6–50.6 (Cα peptide). Analytical HPLC: tR = 16.4 min, ESI
mass spectrum: 999.7 m/z, [M + H]+ (calcd 999.0).
Synthesis of the compounds
trans,cis-RuCl2(CO)2(cppH-RRPYIL-κNp) (7). This bioconju-
gate was prepared using two diﬀerent approaches: (1) by SPPS
between trans,cis-RuCl2(CO)2(cppH-κNo) (2) and RRPYIL, and
(2) by treating the trans,cis,cis-RuCl2(CO)2(dmso-O)2 (3) precur-
sor with an equimolar amount of cppH-RRPYIL in aqueous
solution.
(1) The SPPS coupling between the hexapeptide RRPYIL
and trans,cis-RuCl2(CO)2(cppH-κNo) (2) was performed using
PyBOP/DIPEA/Ru(II): compound 2 (68.7 mg, 5 equiv.) was pre-
activated with PyBOP (83.3 mg, 5 equiv.) and DIPEA (55 μL, 10
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equiv.) in DMF (1 mL) for 1 min, mixed with the resin and
shaken for two days in light protected conditions. The cleavage
and deprotection were done using TFA/phenol/TIS in 85 : 10 : 5
ratio (450 μL) for 2 h. The cleaved compound was precipitated
with ice-cold diethyl ether (5 mL), centrifuged and washed two
times with diethyl ether (5 mL) and then lyophilized and puri-
fied using semi-preparative HPLC. Yield of purified product:
10.9 mg (0.02 mmol, 62%).
(2) A 15.0 mg amount of trans,cis,cis-RuCl2(CO)2(dmso-O)2
(3) (0.039 mmol) was partially dissolved in 2.5 mL of water.
One equivalent of cppH-RRPYIL (39.0 mg, 0.039 mmol) was
added and the mixture was stirred for two days at room temp-
erature in light protected conditions. A clear yellow solution
was obtained in 1 h, and then the color turned progressively to
orange. The final solution was lyophilized and purified using
semi-preparative HPLC. Yield of purified product: 28.8 mg
(0.023 mmol, 60%). [C50H70N16Cl2O10Ru]: (MW: 1226.6).
Selected 1H NMR resonances (DMSO-d6), δ (ppm): 9.81 (d, 1H,
H6), 9.40 (d, 1H, NH), 9.31 (d, 1H, H6′), 9.15 (d, 1H, H3′), 9.17
(br s, 1H, OH Tyr), 8.53 (t, 1H, H4′), 8.40 (d, 1H, NH), 8.29 (d,
1H, H5), 8.06 (t, 1H, H5′), 7.88–7.82 (m, 4H, NH), 6.99, 6.62 (d,
4H, H2,6 and 5,3 Tyr) 4.65–4.10 (m, 6H, Hα peptide). Selected
13C NMR resonances from the HSQC spectrum (DMSO-d6), δ
(ppm): 163.3 (C6), 154.2 (C6′), 141.4 (C4′), 130.9 (C5′), 130.2 (C
Tyr), 127.6 (C3′), 121.0 (C5), 115.5 (C Tyr), 59.5–50.6 (Cα
peptide). Analytical HPLC: tR = 18.2 min, ESI mass spectrum:
1227.3 m/z, [M + H]+ (calcd 1227.0).
[Ru([9]aneS3)(cppH-RRPYIL-κNp)(PTA)]Cl2 (8). A 25.0 mg
amount of Ru([9]aneS3)Cl2(PTA) (6, 0.050 mmol) was dissolved
in 1 mL of water. One equivalent of cppH-NT (50.0 mg,
0.050 mmol) was added and the mixture was heated at 80 °C
for 8 h. The clear yellow solution, obtained within minutes,
turned progressively orange. The final solution was lyophilized
and purified using semi-preparative HPLC. Yield of purified
product: 43.2 mg (0.03 mmol, 60%). [C60H94N19Cl2O8PS3Ru]:
(Mw: 1509.5). Selected
1H NMR resonances (DMSO-d6), δ
(ppm): 9.27 (m, 4H, H6 + H3′ + NH + OH Tyr), 8.82 (d, 1H,
H6′), 8.43 (m, 2H, H4′ + NH), 8.12 (d, 1H, H5), 7.89 (m, 2H,
H5′ + NH), 7.83 and 7.74 (2d, 2H, NH), 7.01 and 6.62 (2d, 4H,
H2,6 and 5,3 Tyr) 4.70–4.10 (m, 6H, Hα peptide). Selected 13C
NMR resonances from the HSQC spectrum (DMSO-d6), δ
(ppm): 163.4 (C6), 154.8 (C6′), 140.0 (C4′), 130.9 (C5′), 130.5
(Tyr), 127. 9 (C3′), 121.4 (C5), 115.2 (Tyr), 59.5–51.1 (Cα
peptide). 31P{1H} NMR spectrum (DMSO-d6), δ (ppm): −39.1
(br s, 1P, PTA trans to S). Analytical HPLC: tR = 16.6 min, ESI
mass spectrum: 1438.6 m/z, [M − H+]+ (calcd 1438.0).
[Ru([9]aneS3)Cl(cppH-κNp)]Cl (10). A 30.0 mg amount of
Ru([9]aneS3)Cl2(dmso-S) (9) (0.068 mmol) was dissolved in
2 mL of water. One equivalent of cppH (18.6 mg, 0.068 mmol)
was added and the mixture was heated to reflux. The clear
orange solution obtained within minutes turned rapidly red.
After 5 h the solution was concentrated to ca. 1 mL. X-ray
quality crystals of the product formed within two days at room
temperature. They were removed by filtration, washed with
cold water and acetone and dried in vacuo (yield: 30.1 mg,
80%). Elemental analysis calcd for [C16H19N3Cl2O2S3Ru]
(MW: 552.9): C 34.72; H 3.46; N 7.59. Found: C 34.76; H 3.40; N
7.52. 1H NMR (D2O + NaCl), δ (ppm): 9.47 (d, 1H, H6), 9.04 (d,
1H, H6′), 8.89 (d, 1H, H3′), 8.22 (t, 1H, H4′), 8.13 (d, 1H, H5),
7.78 (t, 1H, H5′), 2.85 (m, 12H, [9]aneS3). Selected
13C NMR
resonances from the HSQC spectrum (D2O + NaCl), δ (ppm):
162.0 (C6), 152.9 (C6′), 138.8 (C4′), 129.0 (C5′), 126.4 (C3′),
121.4 (C5), 31.2 ([9]aneS3). ESI mass spectrum: 516.2 m/z, [M]
+
(calcd 516.0).
[Ru([9]aneS3)Cl(cppH-RRPYIL-κNp)]Cl (11). A 15.0 mg
amount of Ru([9]aneS3)Cl2(dmso-S) (9) (0.034 mmol) was dis-
solved in 1 mL of water. One equivalent of cppH-NT (17.0 mg,
0.034 mmol) was added and the mixture was heated at 80 °C
for 5 h. The clear yellow solution, obtained within minutes,
turned rapidly red. The final solution was lyophilized and puri-
fied using semi-preparative HPLC. Yield of purified product:
30.8 mg (0.02 mmol, 65%). [C54H82N16Cl2O8S3Ru]: (Mw:
1350.9). Selected 1H NMR resonances (DMSO-d6), δ (ppm):
9.51 (d, 1H, H6), 9.29 (m, 1H, NH), 9.18 (br s, 1H, OH Tyr),
9.11 (d, 1H, H3′), 9.04 (d, 1H, H6′), 8.65 (d, 1H, NH), 8.38 (m,
1H, NH), 8.31 (t, 1H, H4′), 8.11 (d, 1H, H5), 7.89 (m, 1H, NH),
7.82 (m, 2H, H5′ + NH), 6.99 and 6.60 (2d, 4H, H2,6 and 5,3
Tyr), 4.70–4.10 (m, 6H, Hα peptide). Selected 13C NMR reso-
nances from the HSQC spectrum (DMSO-d6), δ (ppm): 163.2
(C6), 153.8 (C6′), 138.6 (C4′), 130.5 (C Tyr), 129.6 (C5′), 126.9
(C3′), 120.0 (C5), 115.2 (C Tyr), 59.5–50.7 (Cα peptide).
Analytical HPLC: tR = 17.5 min, ESI mass spectrum: 1315.8
m/z, [M]+ (calcd 1315.1).
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